Malaria

The device is targeted at severely ill malaria patients who have been hospitalised and prescribed IV drug treatment. These are the most vulnerable patients, including children, pregnant women and immune deficient patients, and can have mortality rates up to 20%.

Latest News

MediSieve CEO Winner of BBSRC Innovator of the Year Award

MediSieve CEO Winner of BBSRC Innovator of the Year Award
Created on 01-08-2019

Dr George Frodsham, founder and CEO at MediSieve, the medical device company developing ‘magnetic b...
Laboratory Technician (Flow Cytometry) Position Open

Laboratory Technician (Flow Cytometry) Position Open
Created on 02-07-2019

MediSieve is looking for a highly motivated Flow cytometry Technician to join their team.